PharmiWeb

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

Judge blocks federal cuts to vaccine recommendations

The decision halts an order by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. to end broad recommendations for all children to be vaccinated against flu, rotavirus, hepatitis A, ...

Her 4-year-old son had successful heart surgery. A few months later, he suddenly died

Jordan was a month shy of his fifth birthday, and 11 weeks out from a successful open heart surgery, when he suddenly died.

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

Detailed price information for Fennec Pharmaceuticals Inc (FRX-T) from The Globe and Mail including charting and trades.
GlobalData on MSN

RFK Jr’s vaccine overhaul halted by federal judge’s ruling

The court ruling reverses several changes by the CDC’s vaccine panel to childhood immunisation recommendations.

A channel opens and a breakthrough lets cystic fibrosis patients breathe

After false starts and incremental gains, scientists crack the problem that made breathing impossible. Will answers come fast ...

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real--World Evidence, Long--Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...
Daily Herald

Lurie gives new details as it advances plan for children’s hospital in Downers Grove

Ann and Robert H. Lurie Children’s Hospital is advancing its plans to build a second hospital in Downers Grove. Hospital officials held an open house Thursday night to answer questions from the ...

Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
TMCnet

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
PharmiWeb

Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-girdle Muscular Dystrophy

Four patients with LGMD-R5 (gamma-sarcoglycanopathy, formerly LGMD-2C) have received the ATA-200 gene therapy as part of the ongoing Phase 1b/2 trial evaluating the safety, pharmacodynamics, and ...

TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...